Nice停止为罕见淋巴瘤提供CAR T细胞治疗资金, 理由是病人生命危在旦夕。 UK charities challenge Nice's halt of CAR T-cell therapy funding for rare lymphoma, citing patient lives at stake.

包括英国血液癌症,淋巴瘤行动和安东尼·诺兰在内的慈善机构已上诉英国国家卫生和护理卓越研究所 (尼斯) 的决定,停止为Tecartus提供资金,T细胞治疗地幔细胞淋巴瘤,这种罕见的血液癌症每年影响英国约600人. Charities including Blood Cancer UK, Lymphoma Action, and Anthony Nolan have appealed a decision by the UK’s National Institute for Health and Care Excellence (Nice) to stop funding Tecartus, a CAR T-cell therapy for mantle cell lymphoma, a rare blood cancer affecting about 600 people annually in the UK. 治疗是这一疾病的唯一一种治疗,以前通过癌症药物基金提供,同时收集了更多的数据。 The treatment, the only one of its kind for this condition, was previously available through the Cancer Drugs Fund while more data was gathered. 尼斯得出的结论是,在现实世界的NHS使用上不如临床试验使用上表现得那么好,指出中位存活率为2.5年,而试验为4年。 Nice concluded it did not perform as well in real-world NHS use as in clinical trials, citing a median survival of 2.5 years compared to four years in trials. 慈善组织认为,这一决定破坏了选择很少的病人获得关键治疗的机会,突出了66岁的保罗·马德利在治疗后恢复健康等病人的证词。 The charities argue the decision undermines access to a critical treatment for patients with few options, highlighting patient testimonials like that of 66-year-old Paul Madley, who regained his health after treatment. 虽然已经接受治疗的病人可以完成治疗,但上诉对评估进程提出了挑战,要求重新考虑,Nice确认将通过既定程序审查关注问题。 While patients already on the therapy can complete it, the appeal challenges the assessment process and calls for reconsideration, with Nice confirming it will review the concerns through established procedures.